FDA places Atara’s Biothearapeutics’ cancer, autoimmune therapies on hold
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.
Drugs
Health
Pharma
Daiichi Sankyo sets up robotic lab in US to speed up drug discovery
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.
Drugs
Pharma
Research
New insights on GLP-1 drugs: Benefits and risks unveiled
HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.
Health
Medical
Pharma
US to withdraw from WHO after an executive order from Donald Trump
The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19.
Drugs
Health
Pharma
AstraZeneca’s medicine to treat a type of breast cancer gets US nod
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs
Health
Pharma
US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
Health
Pharma
Research
Beyond body mass index, experts hone in on new definition of obesity
Obesity, as defined by the standard body mass index, is erroneous, and the condition should be split into two — pre-clinical and clinical,.
Health
Medical
Pharma
Eight people die in Tanzania due to possible Marburg virus disease: WHO
At least eight people have died in Tanzania of suspected Marburg Virus Disease (MVD) and the regional risk is “high,” according to a.
Drugs
Health
Pharma
Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.
Drugs
Medical
Pharma
Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.